Specific targeting of human hepatocellular carcinoma cells by immunoliposomes in vitro

Darius Moradpour, Béatrice Compagnon, Byron E. Wilson, Claude Nicolau, Jack R. Wands – 1 November 1995 – The monoclonal antibody AF‐20 was raised against the human hepatocellular carcinoma (HCC) cell line FOCUS and binds with high affinity to a rapidly internalized 180‐kd homodimeric glycoprotein that is abundantly expressed on the surface of human HCC and other human cancer cell lines. Immunoliposomes were produced by covalently coupling AF‐20 to liposomes containing carboxyfluorescein.

The influence of a maternal chronic hepatitis B virus infection on the repertoire of transcribed T‐cell receptor beta chain variable region genes in human cord blood

William G. H. Abbott, Arie Geursen, John D. Fraser, John Marbrook, Margot A. Skinner, Paul L. J. Tan – 1 October 1995 – We used an anchor polymerase chain reaction method to compare the repertoires of transcribed T‐cell receptor β chain variable region (Vβ) genes in cord blood T cells from neonates of hepatitis B surface antigen (HBsAg) positive (n = 40) and HBsAg negative (n = 40) women. Fifteen of the HBsAg positive women were hepatitis B e antigen (HBeAg) positive, and 25 were HBeAg negative.

Interferon gamma production by peripheral blood lymphocytes to hepatitis C virus core protein in chronic hepatitis C infection

Kazuo Iwata, Takaji Wakita, Akihiko Okumura, Kentaro Yoshioka, Masahiro Takayanagi, Jack R. Wands, Shinichi Kakumu – 1 October 1995 – Evidence suggests that cellular immunity to hepatitis C virus (HCV) core protein may be important in the pathogenesis of viral infection. Therefore, interferon gamma (IFN‐γ) production by peripheral blood mononuclear cells (PBMC) derived from patients with chronic HCV infection (genotype 1b) was examined. The cellular immune response was evaluated with a recombinant HCV core fusion protein derived from a patient with genotype 1b.

Inhibition of woodchuck hepatitis virus replication by adenine arabinoside monophosphate coupled to lactosaminated poly‐L‐lysine and administered by intramuscular route

Luigi Fiume, Giuseppina Di Stefano, Corrado Busi, Alessandro Mattioli, Maria Rapicetta, Roberto Giuseppetti, Anna Rita Ciccaglione, Claudio Argentini – 1 October 1995 – We prepared a hepatotropic conjugate, suitable for intramuscular (IM) injection, of lactosaminated poly‐Llysine with adenine arabinoside monophosphate (ara‐AMP), a drug active against hepatitis B virus (HBV). We studied its organ distribution in mice and its antiviral activity in woodchucks that are carriers of woodchuck hepatitis virus (WHV).

Role of hepatitis C virus in dual and triple hepatitis virus infection

Yun‐Fan Liaw – 1 October 1995 – Hepatitis B virus (HBV), hepatitis C virus (HCV), and hepatitis delta virus (HDV) share same transmission routes, thus dual or triple infection may occur and even persist in the same patients. A significant amount of literature has accumulated since the advent of HCV assays. It is pertinent to review and evaluate the clinical and virological significance of HCV in multiple hepatotropic viral infection. The reported series on seroprevalence of HCV indicate that HCV is found in more than 10% of HBV‐ or HDV‐infected patients worldwide.

Utility of hepatitis C virus RNA determinations in hepatic tissue as an end point for interferon treatment of chronic hepatitis C

Ahmet Gurakar, Stefano Fagiuoli, Hawazin Faruki, Nicola De Maria, Mujdat Balkan, David H. Van Thiel, Lois Friedlander – 1 October 1995 – A total of 41 patients with chronic hepatitis C virus (HCV) defined as abnormal liver injury test results for 6 months or more and HCV RNA positivity in plasma were studied to determine if the liver might not be the only focus of HCV infection in individuals treated with interferon alfa (IFN‐α). All patients were examined for the presence of confounding liver disease and tested negatively for such findings.

Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C

Michele Martinot‐Peignoux, Patrick Marcellin, Mièle Pouteau, Corinne Castelnau, Nathalie Boyer, Marc Poliquin, Claude Degott, Isabelle Descombes, Véronique Le Breton, Véronica Milotova, Jean Pierre Benhamou, Serge Erlinger – 1 October 1995 – The aim of the study was to determine the respective influence of pretreatment serum hepatitis C virus (HCV) RNA levels and HCV genotype on the response to interferon (IFN) alfa in patients with chronic hepatitis C. We retrospectively studied 141 patients with chronic hepatitis C included in two consecutive controlled trials of IFN alfa.

Introduction of a murine p53 mutation corresponding to human codon 249 into a murine hepatocyte cell line results in growth advantage, but not in transformation

Luba Dumenco, Delphine Oguey, Justina Wu, Norma Messier, Nelson Fausto – 1 October 1995 – The p53 gene is frequently mutated in human tumors; in hepatocellular carcinomas, there is a high frequency of a specific mutation at codon 249 in regions with significant aflatoxin exposure. To assess the role of this p53 mutation in the development of hepatocellular carcinoma, a mutant murine p53 gene, p53ser246, which corresponds to human codon 249, was transfected into a differentiated, nontransformed hepatocyte cell line AML12.

Subscribe to